Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

A Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.

Trial Details

NCT ID
NCT07333430
Phase
PHASE1
Sponsor
Hadassah Medical Organization
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Naive HBI0101 CAR-T
Locations (sample)
  • Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

  • ≥18 years of age at the time of signing informed consent.
  • Voluntarily signed informed consent form.
  • Diagnosis of relapsed/refractory multiple myeloma (Parts 1a and 1b), with measurable disease at screening visit as follows:
  • Multiple Myeloma (at least one of the criteria below):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →